X
    X
    X
    X

    Novartis Series D-3 Financing

    In September 2011, our lawyers represented Novartis Bioventures in the $23,000,000 Series D-3 Financing for Tokai Pharmaceuticals, Inc. Tokai Pharmaceuticals, Inc., based out of Cambridge, Massachusetts, ia a biopharmaceutical company , focusing on developing new treatments for prostate cancer. Novartis Bioventures, is a venture fund also based in Cambridge, Massachusetts.

    Disclaimer

    Please understand that your communications with Locke Lord LLP through this website do not constitute or create an attorney-client relationship with Locke Lord LLP. Any information you send to Locke Lord LLP through this website is on a non-confidential and non-privileged basis. Therefore, do not send or include any information in your email that you consider to be confidential or privileged.